Novartis' first-in-class drug Iptacopan to be included in breakthrough therapy
Time of Update: 2022-05-22
On March 14, CDE's official website showed that Novartis' LNP023 capsules are intended to be included in the breakthrough therapy program for C3 glomerulopathy (C3G)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Chia Tai Tianqing's onslaught of innovative drugs This year, 7 class 1 new drugs were approved for clinical use
Time of Update: 2022-05-17
On April 19, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis .
In 2022, the "close relatives" of Class 1 innovative drugs will accelerate the launch of the outbreak
Time of Update: 2022-05-17
From the perspective of new improved chemical drugs (excluding new indications) approved from 2020 to the present, there are a total of levoornidazole tablets from Shenghe Pharmaceuticals, olanzapine oral dissolving film from Hansoh, and montelukast from Qilu Pharmaceuticals.
The large variety of anti-gout was "cut in half", and 4 new drugs of class 1 of traditional Chinese medicine were strongly filled
Time of Update: 2022-05-17
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
Hengrui Medicine's Class 1 New Drugs Hit the 30 Billion Antithrombotic Drug Market
Time of Update: 2022-05-15
Market sales of terminal antithrombotic drugs in public medical institutions in China (unit: ten thousand yuan) Source: Minet.
AstraZeneca/Daisankyo ADC therapy plans to be included in the priority review of Class 1 new
Time of Update: 2022-05-12
Breast cancer | AstraZeneca/Daiichi Sankyo ADC therapy proposed for priority review> On April 24, the CDE official
The research and development of class 1 new drugs of traditional Chinese medicine is accelerated!
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] In recent years, the traditional Chinese medicine industry has been frequently supported by favorable policies, and the research and development of new Chinese medicine class 1
Domestic pharmaceutical companies are attacking class 1 new drugs, and good news in this field continues
Time of Update: 2022-05-02
In recent years, with the continuous improvement of the research and development capabilities of domestic pharmaceutical
Osaikang has accumulated a lot to release the first class 1 new drug benchmarking 4 billion varieties!
Time of Update: 2022-05-01
with PD-1/L1 antibody showed a significant synergistic anti-tumor effect, and also effectively inhibited the metastasis of cancer cells . In the field of anti-tumor drugs, Osaikang's first class 1
Osaikang has accumulated a lot, and the first class 1 new drug is benchmarked against 4 billion varieties!
Time of Update: 2022-05-01
with PD-1/L1 antibody showed a significant synergistic anti-tumor effect, and also effectively inhibited the metastasis of cancer cells . In the field of anti-tumor drugs, Osaikang's first class 1
BeiGene's 22 Class 1 New Drugs Are Eye-catching, Over 10 New Drugs "Going Overseas to Take the Test"
Time of Update: 2022-05-01
million US dollars (about 4 billion yuan) . 22 class 1 new drugs under development are eye-catching, many of which are sprinting for the first domestic BeiGene Some innovative drugs under development
State Food and Drug Administration: Opinions on matters related to the filing of Class I medical devices
Time of Update: 2022-05-01
On March 2, the General Department of the State Food and Drug Administration issued a public solicitation for comments on the "Announcement on Matters Concerning the Filing of Class I Medical Devices (Draft for Comment)" .
Qilu's QLS31906 for Class 1 biological drug injection was approved to enter the 100 billion market
Time of Update: 2022-05-01
On February 18, the CDE official website showed that QLS31906, a class 1 biological drug for injection of Qilu Pharma, has obtained an implied license for clinical trials and is intended
Tide Pharma's first-class innovative drug for pneumoconiosis was approved for clinical use
Time of Update: 2022-04-30
Ted Pharmaceuticals revealed that TDI01 has completed Phase I clinical trials in the United States with good safety, and is currently conducting bridging trials in China .
This pharmaceutical company has 3 new Class 1 drugs that are about to be launched, and the Nuggets ADC track
Time of Update: 2022-04-23
, and the corresponding targets of RC88 (MSLN) and RC118 (CLDN18) are not currently available in the world . In addition, Rongchang Bio has 10 drug candidates that are still in the IND preparation stage
-
-
-
-
Neurology: How are different drug classes associated with periodic limb movements (PLMs)?
Time of Update: 2022-04-22
Periodic Limb Movements (PLMs) Diabetic Vascular Here, we sought to explore the association of broad drug classes with PLM frequency, while controlling for the effects of known risk factors for PLM in a large patient cohort .
The listing application of Huiyu Pharmaceutical's Class 4 generic drug Octreotide Acetate Injection has entered the stage of administrative approval
Time of Update: 2022-04-17
Application of Consistency Evaluation of Octreotide Acetate Injection (including new classification report) Source: Minet.
Pharmaceutical companies are scrambling to develop Class 1 new drugs, and new progress continues!
Time of Update: 2022-04-15
;D and listing of Class 1 new drugs . A key clinical trial of CSPC’s new class 1 drug JMT103 reached the preset endpoint A few days ago, CSPC announced that the company’s
This week, 11 new class 1 drugs were approved for clinical use!
Time of Update: 2022-03-09
Administration, since 2022, 118 clinical trial applications have passed the "implicit license" . This week, 12 new category 1 drugs (excluding supplementary applications) were added
Welcome to ECHEMI